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ABSTRACT 
Background 
The objective was to determine the cerebrovascular risk stratification potential of 
baseline degree of stenosis, clinical features and ultrasonic plaque characteristics in 
patients with asymptomatic internal carotid artery (ICA) stenosis. 
Methods  
This was a prospective, multicentre, cohort study of patients undergoing medical inter-
vention for vascular disease. Hazard ratios for ICA stenosis, clinical features and 
plaque texture features associated with ipsilateral cerebrovascular or retinal ischemic 
(CORI) events were calculated using proportional hazards models. 
Results 
1121 patients with 50-99% asymptomatic ICA stenosis in relation to the bulb (ECST 
method) were followed-up for 6-96 (mean 48) months. A total of 130 ipsilateral CORI 
events occurred. Severity of stenosis, age, systolic blood pressure, increased serum 
creatinine, smoking history of more than 10 pack-years, history of contralateral  TIAs 
or stroke, low gray scale median (GSM), increased plaque area, plaque types 1, 2 and 
3 and presence of discrete white areas without acoustic shadowing (DWA) were asso-
ciated with increased risk. 
ROC curves were constructed for predicted risk vs. observed CORI events as a 
measure of model validity. The area under the ROC curves in a model of stenosis 
alone, a model of stenosis combined with clinical features and a model of stenosis 
combined with clinical and plaque features was 0.59 (95% CI 0.54 to 0.64), 0.66 (0.62 
to 0.72) and 0.82 (0.78 to 0.86) respectively.  
In the last model, stenosis, history of contralateral TIAs or stroke, GSM, plaque 
area and DWA were independent predictors of ipsilateral CORI events. Combinations 
of these could stratify patients into different levels of risk for CORI and stroke, with a 
predicted risk close to the observed. Of the 923 patients with ≥70% stenosis, the pre-
dicted five year percentage stroke rate was <5% in 495, 5-9.9% in 202, 10-19.9% in 
142 and ≥20% in 84 patients. 
Conclusions 
Cerebrovascular risk stratification is possible using a combination of clinical and ultra-
sonic plaque features. These findings need to be validated in additional prospective 
studies in patients having current medical intervention. 
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INTRODUCTION 
Studies performed in the 1980s and 1990s(1-10) have indicated that the risk of stroke 
in asymptomatic patients is 0.1-1.6% per year for internal carotid artery (ICA) stenosis 
<75-80% (NASCET method i.e. in relation to the diameter of the normal distal internal 
carotid artery) and 2.0-3.3% per year with greater degrees of stenosis.  
 Two randomized controlled trials, the ACAS in 1995(11) and ACST in 2004(12) 
reported that in patients with asymptomatic ICA stenosis >60-70% (NASCET) carotid 
endarterectomy reduced the risk of stroke from 2% to 1% per year(11,12). In these 
trials carotid endarterectomy was associated with a 2-3% perioperative rate of stroke 
or death. However, medical intervention which was left to the discretion of the local 
teams was suboptimal in relation to current practice. Statins and antiplatelet agents 
were administered to only 25% and 80% of patients respectively(12).  
 Currently, vascular disease medical intervention includes ongoing risk factor 
diagnosis, patient education, support of healthy life style practices and medications. 
Best evidence indicates that the average annual risk of ipsilateral cerebral and any ter-
ritory stroke among patients with asymptomatic severe ICA stenosis receiving medical 
intervention alone has fallen to approximately 1%(13,14) making routine carotid 
endarterectomy unjustified. However, if patient subgroups with sufficiently higher than 
average risk, despite current optimal medical intervention, could be reliably identified, 
then carotid surgery may still be justified.  
  Studies of duplex-determined carotid plaque images have found that hypoecho-
ic (echolucent, mainly black) and heterogenous plaques (plaques with mixed black 
and white areas) are more often associated with cerebrovascular symptoms than 
those which are hyperechoic (uniformly white or calcified)(1,2,15-20). Two recent pro-
spective studies have demonstrated that hypoechoic plaques with low gray-scale me-
dian (GSM) were associated with a 3-4 fold increase in stroke(21,22). Other duplex-
determined plaque features reported to be associated with symptomatic plaques are 
plaque area and plaque volume(23). However, the potential of such methods when 
combined in stratifying the risk of ipsilateral stroke/TIA in patients with asymptomatic 
carotid stenosis has not been investigated. Limitations of previous ultrasound studies 
of carotid plaque morphology include retrospective design, small samples, lack of 
subcategorisation of stenosis severity and lack of differentiation between ipsilateral 
and any territory ischemic symptoms.  
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 The Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study, was a 
multicentre cohort study of patients with asymptomatic ICA stenosis undergoing vas-
cular disease medical intervention alone. The objective was to assess the cerebrovas-
cular risk stratification potential of combinations of patients’ clinical and biochemical 
characteristics, ultrasound-determined degree of stenosis and plaque morphology. 
 
METHODS 
Patient Recruitment 
Inclusion criteria 
Newly referred (<3 months) patients with 50-99% ICA stenosis in relation to the carot-
id bulb diameter (ECST method) without previous ipsilateral cerebral or retinal ischem-
ic (CORI) symptoms and without neurological abnormality were recruited to the study 
after written informed consent. Patients who had had contralateral cerebral hemi-
spheric/retinal or vertebrobasilar symptoms or signs of stroke/TIA were included if 
asymptomatic for at least 6 months prior to recruitment.  The ratio of recruited patients 
with stenosis 50-69% and 70-79% (ECST) from each centre was 1:2. For patients with 
bilateral asymptomatic carotid atherosclerosis the side with the more severe stenosis 
was considered ipsilateral (the study artery). 
Exclusion criteria 
Patients who could not attend for a 6 monthly neurological assessment and those with 
a life expectancy of less than two years were excluded. 
Recruitment sources 
The participating centers, their eligibility criteria and quality control procedures have 
been published previously(24-27) and are summarized in the on line data supplement. 
Study Approval  
Approval was obtained from the Multicenter Research Ethics Committee (North 
Thames, London, UK) and local ethics committees. 
 
Clinical and Biochemical Characteristics 
At baseline all patients had a history taken and a physical examination by the local 
neurologist,  electrocardiographic (ECG) examination and collection of fasting blood 
for determination of the following: 
 - Age, gender, body mass index (BMI), systolic and diastolic blood pressure, 
smoking history and accrued pack-years. 
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 - Medication usage including antiplatelet, anti-hypertensive and lipid lowering 
agents. 
 - Presence of hypertension (antihypertensive medication or BP≥140 mmHg 
systolic or ≥90 mm Hg diastolic); coronary artery disease (documented myocardial in-
farction/angina, coronary artery bypass or stenting); diabetes (antihyperglycemic ther-
apy or fasting blood glucose >120 mg/dL) and previous contralateral stroke/TIA or ver-
tebrobasilar symptoms. 
 - ECG evidence of atrial fibrillation, previous myocardial infarction (MI), myo-
cardial ischemia and left ventricular hypertrophy (LVH) on baseline ECG according to 
previously published criteria(25). ECGs were reported at the coordinating centre by 
two cardiologists. 
 - Fibrinogen, fasting lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides), serum creatinine and hematocrit. 
 
Duplex Examination  
Bilateral carotid duplex scanning was performed on admission to the study. Ultraso-
nographers from all centres were trained at the coordinating centre in grading internal 
carotid stenosis and plaque image capture(24). The entire duplex examination, rec-
orded on S-VHS videotape, was sent to the coordinating centre for quality control.  
 
Grading of internal carotid stenosis 
A combination of velocity criteria were used to express the degree of stenosis in terms 
of both the ECST method and the NASCET method(24,28) (see on line data supple-
ment for duplex criteria). ECST stenosis was used in analysis because of its linear re-
lation to risk of ipsilateral CORI events, unlike NASCET stenosis which has an S-
shaped relationship(27). Contralateral ICA occlusion was noted. Bilateral vertebral ar-
tery flow was reported as cephalad, reversed or not visualised.  
 
Image normalization, segmentation and analysis  
Baseline images from video recordings were digitized off-line on a PC using a video 
grabber card (Videologic, TV Snap version 1.0.3 c 1994) at a resolution of 640x480 
pixels at the coordinating center by two members of the team who were experienced 
in carotid scanning. Image normalization for gray-scale using linear scaling with 
“blood” (gray-scale=0) and adventitia (gray-scale=190), and pixel density standardiza-
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tion to 20 pixels per mm were performed followed by image analysis. The “Plaque 
Texture Analysis software” version 3.2 (Iconsoft International Ltd, PO Box 172, Green-
ford, London UB6 9ZN, UK)(29) was used. Some plaque texture features were auto-
matically calculated using the “Feature Extraction” module of the software (GSM(29), 
modified Geroulakos plaque classification(18,26) and plaque area), while presence of 
discrete white areas without acoustic shadowing (DWA) and ulceration were identified 
visually. 
 
Outcome Measures 
Primary outcome measures were (a) ipsilateral CORI events i.e. cerebral or retinal is-
chemic events which included stroke and (b) ipsilateral cerebral ischemic stroke (fatal 
or non-fatal). Stroke and TIA were defined as cerebral deficits of most likely vascular 
origin lasting >24 hours or <24 hours, respectively. When a stroke was reported, de-
tails recorded by the local neurologist, a 6-month modified Rankin score(30) and CT or 
MRI brain scan results were requested. Two coordinating centre members including a 
neurologist, made the final classification of ipsilateral strokes. Local team members 
diagnosed TIAs and amaurosis fugax. 
 Secondary outcome measures were all other strokes and TIAs, contralateral 
retinal vascular events and all other deaths. Cause of death was determined by local 
team members, using death certificates, hospital records and family doctor infor-
mation.  
 
Study Exit Points 
Follow-up ceased with the first occurrence of any of the following: the first primary out-
come measure, carotid endarterectomy/angioplasty or stenting for the still asympto-
matic study artery, death from causes other than ipsilateral stroke or loss to follow-up. 
 Stroke, TIA or death associated with carotid endarterectomy/angioplasty or 
stenting for the still asymptomatic study artery were not included in event rate calcula-
tions. 
 
Statistical Analysis 
Stata® (versions 10.1 and 11; StataCorp, 4905 Lakeway Drive, College Station, Texas 
77845 USA) was used for statistical analysis and production of graphs. 
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Initially, Kaplan-Meier curves were used for the whole cohort of 1121 patients to 
determine overall ipsilateral CORI event and stroke free survival over time. Stratified 
Kaplan-Meier curves were also constructed for % stenosis, history of contralateral 
TIAs or stroke, discrete white areas, plaque area and GSM. Continuous variables 
were categorised for stratified Kaplan-Meier plots. For example, stenosis was catego-
rized as mild (<70% ECST/<50% NASCET), moderate (70-89% ECST/50-82 
NASCET) or severe (90-99% ECST/ 83-99% NASCET). 
 Subsequently, hazard ratios for clinical, biochemical and ultrasonic features for 
ipsilateral CORI events and stroke were determined using an unadjusted Cox model 
for each variable. Continuous risk factors were transformed to an un-skewed distribu-
tion where possible. 
Risk factors which were significant at p<0.05 in unadjusted models for CORI 
events or stroke were considered in multivariable proportional hazards models. Flexi-
ble parametric models of Royston & Parmar(31) were used because the baseline haz-
ard function at 5 years was of interest, which is erratic in Cox models. Hazard ratios 
from these models were compared to equivalent Cox models. Model (i) included ste-
nosis and the significant clinical factors to predict time to CORI event; model (ii) in-
cluded stenosis, the significant clinical factors and plaque features as covariates; 
model (iii) was formulated identically to (ii) except the dependent variable was time to 
stroke. Variable selection was not used in model (iii) because of the smaller number of 
events. Important prognostic variables were selected using backwards elimination, 
with p>0.05 as the condition for a variable to be excluded. To relax the assumption 
that the effect of covariates on the dependent variable must be linear, multivariable 
fractional polynomials were used(32). 
 On the basis of model (iii) ipsilateral cerebral ischemic stroke free survival 
curves were produced for different combinations of risk factor subgroups from which 
5-year stroke rates were calculated. 
The assumption of proportional hazards was tested using the Schoenfeld re-
siduals. Harrell’s C(33) and a pseudo R2(34) were calculated for models (i-iii). Harrell’s 
C is a measure of discrimination which calculates the proportion of time that survival 
times for pairs of patients can be correctly ordered, on the basis of covariates in the 
model. Pseudo R2 is analogous to the standard R2 (proportion of explained variation) 
adapted to models for censored survival data. 
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The covariates included in a model were used to calculate the linear predictor 
score, βx (the sum of the product of mean-centred covariate values and correspond-
ing parameter estimates) for each patient. ROC curves were constructed for βx 
against observed 5-year CORI event rates (in the same set of patients). These were 
compared for the unadjusted ECST stenosis model and models (i) and (ii). This was 
also done separately for (iii), since comparison of different βx for different dependent 
variables is inappropriate. For model (iii), internal calibration was assessed by com-
paring predicted risk of stroke at 5 years to the observed proportion experiencing 
stroke by 5 years. 
 
Role of the Funding Source 
Study sponsors had no role in the design, conduct or reporting of this research. 
 
RESULTS 
1121 patients between 39 and 89 years (mean age 70.0, SD 7.7, 61% male) were re-
cruited during 1998-2002 with a follow-up of 6-96 months (mean 48 months). 66% of 
patients were recruited from medical services (vascular internists-28%, neurologists-
16%, cardiologists-10%, hypertension clinics-5%, metabolic units-3% and screening 
programs-4%). 34% of patients were recruited from surgical services (vascular-32%, 
cardiac surgery-2%). Baseline distribution of patient clinical and biochemical charac-
teristics, degree of stenosis and other plaque features are presented in table 1.  
 
Ipsilateral Cerebrovascular Events 
A total of 130 first ipsilateral CORI events occurred (59 strokes of which 12 were fatal, 
49 TIAs and 22 amaurosis fugax). For ischemic stroke the modified Rankin scale at 6 
months was zero in 4 cases, 1 in 9 cases, 2 in 6 cases, 3 in 8 cases, 4 in 18 cases, 5 
in 2 cases and 6 in 12 cases. There were two additional first ipsilateral fatal hemor-
rhagic strokes. 
 
Other outcome measures 
There were 49 first contralateral CORI events (18 ischemic strokes of which 7 were 
fatal, 22 TIAs and 9 amaurosis fugax). There were 2 vertebrobasilar strokes. 
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 There were a total of 214 deaths (195 non-stroke deaths) of which 157 (73%) 
were due to cardiovascular causes: myocardial infarction-110, fatal stroke-19 (12 ipsi-
lateral and 7 contralateral already mentioned above), heart failure-17, pulmonary em-
bolism-3, lower limb ischemia/gangrene-3, ruptured abdominal aortic aneurysm-3, re-
nal failure-1 and mesenteric artery thrombosis-1. There were 56 non-vascular deaths; 
malignancy-37, pneumonia/respiratory failure-12, gastrointestinal hemorrhage-2, de-
mentia-2, road traffic accident-2 and general surgical procedure-1. Cause of death 
was unknown in one patient. 
 Ipsilateral carotid endarterectomy was performed in 129 patients with still 
asymptomatic study artery (stenosis median:85% ECST; interquartile range:75-90) 
because the clinician in charge or the patient requested it. This occurred soon after 
publication of the ACST results. Twenty-one patients have been lost to follow up. In 
these 21 patients contact was lost with 15, 5 declined to re-attend (too old to travel) 
and 1 emigrated. Thus, 150 patients (13.4%) have been “lost” from the study. They 
have been included in the analysis up to the last follow-up visit. The remaining 971 
(86.6%) have been followed up to a primary event, death or termination of the study in 
December 2006. 
Ipsilateral event rates in relation to stenosis severity 
The ipsilateral CORI events and strokes in relation to subgroups of stenosis are 
shown in table 2. They demonstrate that ipsilateral risk increases with increasing ste-
nosis across mild-severe categories. 
 
Baseline features associated with increased ipsilateral cerebrovascular risk 
Hazard ratios for each individual baseline clinical, biochemical and ultrasonic feature 
associated with patients with ipsilateral CORI events and strokes are shown in table 3. 
Ipsilateral stenosis, systolic blood pressure, smoking history of more than 10 pack-
years, GSM, plaque area, plaque type, history of contralateral TIAs or stroke, and 
presence of DWA were significant risk factors for CORI events. The hazard ratios for 
stroke showed a similar pattern, although these were not always statistically significant 
due to the lower number of events. 
Table 4 shows the results of three multivariable proportional hazard models, (i)-
(iii). Measures of model performance Harrell’s C and pseudo R2 were greatly in-
creased by including plaque features. Powers of continuous covariates remained un-
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transformed by multivariable fractional polynomials. Parameter estimates in table 4 
were very similar to those obtained using Cox models in each case. 
 The cumulative ipsilateral CORI event free survival Kaplan-Meier curves for 
each of the significant risk factors in model (ii) are shown in figure 1 (a-e). 
 On the basis of the variables shown in table 4 the linear predictor scores xβ of 
models (i) and (ii) were calculated for each patient. ROC curves constructed with (a) 
stenosis (ECST) as a continuous variable, (b) the predictor score from model (i) and 
(c) the predictor score from model (ii) are shown in figure 2. The predictor score from 
model (ii) that combined stenosis with clinical and plaque texture features was associ-
ated with the largest area under the ROC curve: 0.82 (95% CI 0.77 to 0.85) (Figure 
2a). The area under the ROC curve from model (iii) which had stroke as the depend-
ent variable was 0.80 (95% CI 0.74 to 0.87)(Figure 2b). 
On the basis of model (iii) ipsilateral cerebral stroke probabilities at five years 
were produced for different combinations of risk factor subgroups (Table 5). (To calcu-
late individual patient risk, please refer to appendix.) Figure 3 shows calibration for 
model (iii). At low predicted probabilities the model seems to slightly over-predict. At 
higher predicted probabilities the model predicts very nicely, with estimates close to 
the line of agreement and confidence intervals overlapping. The predicted five year 
percentage stroke rate (observed; 95% CI) was <5% (very low risk) in 654 (1%; 0.2 to 
2), 5-9.9% (low risk) in 225 (8%; 5 to 13), 10-19.9% (moderate risk) in 156 (12%; 7 to 
18) and ≥20% (high risk) in 86 patients (29%; 14 to 33). Of the 923 patients with ≥70% 
stenosis, 495 were included in the very low, 202 in the low, 142 in the moderate and 
84 in the high risk group. 
 
DISCUSSION 
The ACSRS study is the largest prospective study of patients with asymptomatic ca-
rotid artery stenosis. The results demonstrate that a number of baseline clinical char-
acteristic s and ultrasonic plaque features are independent predictors of subsequent 
ipsilateral CORI events. Clinical features added to stenosis improve prediction and the 
further addition of plaque features improves prediction even more as shown by the in-
creased area under the ROC curves (Fig. 2) 
The inclusion criteria in our study provided a wide range of stenosis (50-99% 
ECST). This allowed classification into subgroups of mild, moderate and severe de-
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gree of stenosis and better evaluation of this risk factor in contrast to other published 
studies that had excluded upper or lower extremes of the range of stenosis(1-8). Be-
cause ECST stenosis is linearly related to ipsilateral CORI event and stroke risk and 
NASCET stenosis is not(27), the ECST measurement has been used in the analysis 
of our data. Only one previous prospective study  has recruited patients within the full 
range of 50-99% ECST stenosis as used in our study(7) and graded the stenosis as 
mild (<50%), moderate (50-79%) and severe (80-99%). This study which involved 678 
patients with a mean follow-up of 3.6 years showed an increasing ipsilateral CORI 
event and stroke rate with increasing grades of stenosis. 
Smoking is an established risk factor for plaque progression, plaque rupture 
and ischemic stroke(35,36). The increased risk for ipsilateral stroke in patients with a 
history of contralateral symptoms has been observed also in the medical arm of the 
ACST trial. In ACST, at 5 years, there were 56 strokes in 1057 patients without and 39 
strokes in 375 patients with a history of contralateral symptoms (OR 2.06 95% CI 1.35 
to 3.16)(12). 
Mild to moderately raised serum creatinine is an independent predictor of car-
diovascular risk and particularly ischemic stroke in asymptomatic individuals and pa-
tients with peripheral vascular disease(37,38). In our study creatinine levels higher 
than 100 µmol/L were associated with hypoechoic plaques (data not shown). 
Other established risk factors such as hypertension and hypercholesterolemia 
were either weakly associated with CORI events or not significant probably because 
they were present in the majority of the patients. 
Carotid plaque area and plaque volume have already been reported to be 
strong predictors of myocardial infarction and stroke(23) in patients with mild degrees 
of stenosis. Our results show that plaque area can be used to stratify cerebrovascular 
risk in patients with plaques producing moderate and severe stenosis (Fig. 1c). 
 The measurement of GSM after image normalization is now an established re-
producible measurement of overall plaque echodensity. Our study confirms the find-
ings of other prospective studies(21,22) that a low GSM is a strong predictor of future 
strokes.  
 Plaque heterogeneity is in many plaques the result of presence of DWA without 
acoustic shadow (i.e. without calcification) in hypoechoic areas. These DWA are often 
hyperperfused as shown by ultrasonic contrast perfusion agents and correspond to 
neovasculariszation and increased numbers of macrophages on histology(39). 
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Whether the presence of these areas are responsible for the development of intra-
plaque hemorrhage, non uniform plaque stresses promoting plaque rupture or erosion 
of the fibrous cap merits further investigation. 
 This study has a number of limitations. Ultrasonic imaging is to a certain extent 
operator dependent. This has been overcome by training ultrasonographers in equip-
ment presets and image capture; also, by performing image normalization with com-
puterized analysis at the coordinating centre (see on line supplement). The im-
portance of training vascular ultrasonographers in equipment settings and plaque im-
aging for optimal results cannot be overemphasized.  
 Another limitation is that the medical management of patients was according to 
what was considered best medical therapy at each centre – the biggest factor when it 
comes to the relevance to current clinical practice. At each centre the clinician in 
charge was free to change therapy according to changing indications. At the beginning 
of the study only 84% of patients were on antiplatelet therapy and only 25% on lipid 
lowering therapy reflecting clinical practice at that time. Towards the end of the study 
these percentages were 95% and 85% respectively. In addition, this “freedom” in 
management resulted in 129 (11.5%) patients having a carotid endarterectomy in the 
absence of symptoms soon after the results of the ACST were published. Despite this, 
follow-up to a CORI event, death or to the end of the study was achieved in 87% of 
patients. 
 The clinical implication of our findings is that the combination of clinical and ul-
trasonic plaque features with stenosis can stratify risk better than stenosis alone and 
this may lead to refinement of the indications for carotid endarterectomy. Validation of 
predicted risk in this study was limited since this was done internally, that is for the 
same group of patients on whom the score was developed. These findings need to be 
validated in additional prospective observational studies using current medical inter-
vention or in the medical arm of randomized controlled trials comparing carotid 
endarterectomy plus medical intervention against medical intervention alone. 
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Table 1 
Baseline clinical, biochemical and ultrasonic features in 1121 patients 
Continuous variables (normal distribution; mean±sd) 
Age (years)       70.0 ± 7.7         
BMI (kg/m2)*       25.4 ± 3.7         
SBP (mmHg)*     152.3 ± 22.2   
DBP (mmHg)*      82.2 ± 10.0       
Creatinine (μmol/L)*   100.5 ± 34.1    
Fibrinogen (g/L)*      3.56 ± 1.00         
Hematocrit (%)*      41.1 ± 4.9          
Total Cholesterol (mmol/dL)*  6.01 ± 1.19         
LDL Cholesterol (mmol/dL)*   3.90 ± 1.20          
HDL Cholesterol (mmol/dL)*  1.30 ± 0.49 
Ipsilateral stenosis (%)   78.0 ± 12.8       
Contralateral stenosis (%)   45.5 ± 30.0 
 
Continuous variables (skewed distribution; median, interquartile range) 
Pack-years              10 (0, 36)          
Triglycerides (mmol/dL)*   1.58 (1.17, 2.19)     
Gray scale median (GSM)      32.2 (17.1, 50.6)              
Plaque area (mm2)       41.9 (27.1, 60.2)         
 
Categorical variables  
Gender: female    438 (39%) 
Smoking at entry    212 (19%) 
Coronary artery disease    379 (34%)  
Atrial fibrillation      29 (2.6%)  
Hypertension     709 (63%)  
Diabetes     231 (21%)  
History of contralateral TIAs or stroke 173 (15%)  
History of vertebro-basilar symptoms 136 (12%)  
Old MI on ECG    201 (18%)  
Ischemia on ECG    238 (21%)  
LVH on ECG     116 (10%)  
Antihypertensive therapy   674 (60%)  
Antiplatelet therapy    940 (84%)  
Lipid lowering therapy   278 (25%) 
Ipsilateral vertebral flow not detected or reversed   90 (8%) 
Contralateral internal carotid occlusion 93 (8%) 
Ipsilateral ultrasonic ulcer     101 (10%) 
Plaque type 4 and 5     186 (17%)  
          3     509 (45%)  
          2    341 (30%)  
          1    85 (8%)  
Presence of discrete white areas  718 (64%) 
* Percentages of missing values were: BMI 4%, SBP 10%, DBP 10%, creatinine 
11%, fibrinogen 23%, hematocrit 12%, total cholesterol 11%, LDL 22%, HDL 22%, tri-
glycerides 12%. 
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Table 2 
 
Ipsilateral cerebral or retinal ischemic (CORI) events (AF, TIAs and stroke) and ipsi-
lateral ischemic cerebral stroke for all patients and subgroups according to ECST ste-
nosis (*) as used in this paper and NASCET stenosis (**) for comparison with previous 
publications that have used these methods. Follow-up 6 months to 8 years (mean: 48 
months). P values were calculated using chi square test for trend. 
 
ECST  NASCET  N CORI events  Strokes 
stenosis (%) stenosis (%) 
All patients   1121 130 (11.6%)    59 (5.3%) 
 
50-69*  < 50  198   16 (8.1%)    5 (2.5%) 
70-89*  50-79  598   65 (10.9%)    29 (4.8%)  
90-99*  80-99  325   49 (15.1%)  25 (7.7%) 
       P = 0.01  P = 0.008 
 
< 80  < 70**  514   50 (9.7%)  21 (4.1%) 
80-99  70-99**  607   80 (13.2%)     38 (6.3%) 
       P = 0.07  P = 0.10 
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Table 3 
Unadjusted hazard ratios (HR) of risk factors for ipsilateral CORI events and ipsilateral 
cerebral stroke. (Skewed continuous predictors were transformed to be approximately 
symmetrically distributed). HR with P<0.05 are in bold 
Risk factor    CORI               
HR 
   95% CI Stroke 
 HR 
   95% CI 
Age (10 yr increase) 1.10 (0.88 to 1.38) 1.42 (1.00 to 2.02) 
BMI (5 unit increase)* 0.86 (0.65 to 1.14) 0.85 (0.57 to 1.28) 
Systolic blood pressure 
 (10 unit increase)* 
 
1.11 
 
(1.07 to 1.22) 
 
1.07 
 
(0.94 to 1.22) 
Diastolic blood pressure 
 (10 unit increase)* 
 
1.21 
 
(0.99 to 1.47) 
 
1.14 
 
(0.86 to 1.50) 
Creatinine (20% increase)* 1.10 (0.96 to 1.25) 1.28 (1.09 to 1.50) 
ln(GSM+40) 0.08 (0.04 to 0.15) 0.06 (0.02 to 0.15) 
Fibrinogen* 1.03 (0.85 to 1.26) 1.17 (0.84 to 1.48) 
Haematocrit (10 unit in-
crease)* 
1.18 (0.83 to 1.66) 1.13 (0.07 to 1.85) 
Total cholesterol* 1.08 (0.92 to 1.26) 1.02 (0.80 to 1.28) 
LDL cholesterol* 1.03 (0.86 to 1.23) 0.97 (0.74 to 1.27) 
HDL cholesterol* 1.12 (0.75 to 1.69) 1.34 (0.80 to 2.24) 
Triglyceride (doubling)* 1.18 (0.80 to 1.74) 1.73 (0.99 to 3.05) 
Ipsilateral. Stenosis 
 (10% increase) 
 
1.02 
 
(1.01 to 1.04) 
 
1.04 
 
(1.01 to 1.06) 
Contralateral stenosis 
 (10% increase) 
 
1.03 
 
(0.98 to 1.10) 
 
1.05 
 
(0.96 to 1.14) 
Plaque area (mm2) 1/3 2.51 (2.01 to 3.12) 2.45 (1.76 to 3.40) 
Plaque type 4&5 1 - 1 - 
3    . 6.31 (1.52 to 
26.19) 
4.41 (0.58 to 33.74) 
2    . 19.66 (4.83 to 
80.06) 
18.79 (2.58 to 
137.03) 
1    . 18.28 (4.20 to 
79.52) 
20.74 (2.63 to 
163.70) 
Male 0.92 (0.65 to 1.30) 1.10 (0.65 to 1.86) 
Smoking 1.10 (0.72 to 1.70) 1.51 (0.84 to 2.71) 
≥10 smoking pack-years 1.65 (1.16 to 2.34) 1.52 (0.90 to 2.56) 
Coronary artery disease 1.19 (0.84 to 1.70) 1.32 (0.78 to 2.21) 
Atrial fibrillation 1.36 (0.50 to 3.68) 1.55 (0.38 to 6.36) 
Hypertension 0.98 (0.68 to 1.40) 1.00 (0.59 to 1.70) 
Diabetes 0.77 (0.48 to 1.25) 0.88 (0.45 to 1.74) 
History of vertebro-basilar 
symptoms 
1.48 (0.92 to 2.38) 1.48 (0.73 to 3.00) 
History of contralateral TIAs 
or stroke 
2.35 (1.60 to 3.43) 3.03 (1.77 to 5.20) 
Old MI on ECG 1.31 (0.87 to 1.97) 1.62 (0.91 to 2.87) 
Ischaemia on ECG 1.41 (0.95 to 2.08) 1.36 (0.76 to 2.45) 
LVH on ECG 1.03 (0.59 to 1.80) 1.15 (0.52 to 2.53) 
Antihypertensive therapy 0.94 (0.66 to 1.34) 0.94 (0.56 to 1.59) 
Antiplatelet therapy 0.98 (0.60 to 1.59) 1.05 (0.50 to 2.20) 
Lipid lowering therapy 0.87 (0.58 to 1.29) 0.81 (0.45 to 1.48) 
Ipsilateral vertebral flow 1.74 (0.88 to 3.42) 3.72 (0.91 to 15.24) 
Contralateral internal carotid 
occlusion 
1.27 (0.71 to 2.25) 1.05 (0.42 to 2.62) 
Ipsilateral ultrasonic ulcer 0.52 (0.24 to 1.11) 0.48 (0.15 to 1.55) 
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Presence of  DWAs (>1) 2.32 (1.49 to 3.6) 1.68 (0.92 to 3.06) 
* Percentages of missing values were: BMI 4%, SBP 10%, DBP 10%, creatinine 11%, 
fibrinogen 23%, hematocrit 12%, total cholesterol 11%, LDL 22%, HDL 22%, triglycer-
ides 12%. 
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Table 4 
Flexible parametric proportional hazards models including significant variables from 
table 3 with ipsilateral CORI events as the dependent variable. (GSM = Gray Scale 
Median; DWA = Discrete White Areas; HR = Hazard Ratio). Selected using backwards 
elimination on all variables with 95% CI not overlapping 1 in table 2.  
 
(i) Clinical factors only. Ipsilateral CORI events as the dependent variable. 
5-year baseline hazard estimated as .886; Harrell’s C = .66; Pseudo R
2
 = .17 
 
Variable         β  HR  95% CI  P 
Stenosis (% ECST)  0.028  1.03  1.01 to 1.04 <0.001 
Pack-years (<10,  ≥10)       0.429  1.53  1.07 to 2.18 0.018 
History of contralateral  0.858  2.36  1.61 to 3.46 < 0.001 
TIAs and/or stroke 
 
(ii) Clinical factors with plaque features. Ipsilateral CORI events as the dependent variable 
5-year baseline hazard estimated as .949; Harrell’s C = .79; Pseudo R
2
 = .55 
 
Variable         β  HR  95% CI  P 
Stenosis (% ECST)  0.01696  1.02  1.00 to 1.03 0.027 
Log(GSM + 40)   -2.4519  0.09  0.04 to 0.17 <0.001 
Plaque area
⅓
 (mm
2
)  0.6539  1.92  1.50 to 2.46 <0.001 
DWA (Present vs. absent)  0.7417  2.10  1.32 to 3.35 0.002 
History of contralateral  0.6901  1.99  1.32 to 2.92 0.001 
TIAs and/or stroke (Yes vs no) 
 
(iii) Clinical factors with plaque features. Ipsilateral hemispheric stroke as the dependent varia-
ble. Note no variable selection was performed here because of too few events. Variables were 
identical to those used in (ii). 
5-year baseline hazard estimated as .972; Harrell’s C = .80; Pseudo R
2
 = .61 
 
Variable         β  HR  95% CI  P 
Stenosis (% ECST)  0.026  1.03  1.00 to 1.05 0.024 
Log(GSM + 40)   -2.672  0.07  0.02 to 0.20 <0.0001 
Plaque area
⅓
 (mm
2
)  0.629  1.88  1.28 to 2.75 <0.0001 
DWA (Present vs. absent)  0.429  1.54  0.81 to 2.92 0.18 
History of contralateral  0.973  2.65  1.54 to 4.54 <0.0001 
TIAs and/or stroke (Yes vs. no) 
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Table 5. Estimated % risk of ipsilateral cerebral stroke within 5 years (for patients with ≥ 
70%  ECST stenosis) 
– denotes a covariate combination which did not occur in observed data 
* denotes a covariate combination which occurred less than five times in observed data 
Stenosis 
History of 
contralateral 
TIAs or stroke DWA present Plaque area (mm²)   GSM   
        >30 
15-
30 <15 
      >80 20.3* 52.8* – 
    Yes 40-80 13.8 35.8 70.0* 
  Present   <40 7.8* 20.1* – 
      >80 13.3* 34.5* – 
    No 40-80  9.0* – 45.7* 
90-99% ECST     <40 5.1* 13.1* 25.7* 
(83-99% NASCET)     >80 7.7* 20.0 39.1* 
    Yes 40-80 5.2 13.5 26.5 
  Absent   <40 2.9 7.6 14.9* 
      >80 5.0* 13.0* 25.5* 
    No 40-80 3.4* – 17.3 
      <40 1.9 5.0 9.7* 
      >80 13.8* 35.0* 70.4* 
    Yes 40-80 9.4 24.4* 47.7 
  Present   <40 5.3 13.7* 26.8 
      >80 9.0* 23.5* – 
    No 40-80 6.1* 15.9* 31.1* 
70-89% ECST     <40 3.4 8.9* 17.4* 
(50-82% NASCET)     >80 5.2 13.6 26.6 
    Yes 40-80 3.5 9.2 18.0 
  Absent   <40 2.0 5.2 10.1 
      >80 3.4* – 17.4 
    No 40-80 2.3 6.0 11.8 
      <40 1.3 3.4 6.6 
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Appendix – Calculation of predicted 5 year stroke free survival 
 
The hazard ratios for covariates presented in table 4 (iii) can be combined with the 
baseline survival function to predict 5-year stroke free survival probabilities for a pa-
tient with a given set of covariates.  
 
For an individual with baseline covariate values (close to mean covariates) as listed in 
table 6 the stroke free survival at 5 years, S0(5y) is estimated as 0.972. 
 
Table 6 Baseline covariates and transformed values in an individual 
Covariate 
Baseline 
value 
Corresponding transfor-
mations 
Stenosis, % 80 None 
GSM 30 ln(GSM+40) = 4.248 
Plaque area, mm2 40mm2 (Plaque area)⅓ = 3.420 
DWA Absent 0 
History of contralateral TIAs and/or 
stroke 
Absent 0 
 
Predicted 5-year stroke free survival for a patient with different values of the covari-
ates in table 6 can be calculated as follows. 
1. Transform continuous covariates using the formulae given in table 6, third col-
umn. 
2. Using these (possibly transformed) values, calculate the differences, x, be-
tween the value you are interested in and the values used in S0(5y) (Table 7, 
second column). 
3. Multiply each of these differences by the corresponding log-hazard ratio, β, 
from table 4(iii) to obtain βx as shown in table 7 column 4. 
4. Sum the values obtained in step 3 above to denote this as βx. 
5. Calculate exp(βx) 
6. Compute predicted survival probability as a percentage for a patient using 100 
x 0.972exp(βx). 
 
Following this calculation for a patient with 90% stenosis, GSM = 10, plaque area = 80 
mm2, DWA present and history of contralateral TIAs and/or stroke absent: 
 
1. ln(GSM+40) = 3.912. (Plaque area)⅓ = 4.309 
 
Table 7 Steps 2 and 3 in the calculation of 5 year predicted stroke free survival 
Variable Calculation 2. x β 3. βx 
Stenosis 90 – 80 10 0.026 0.2600 
ln(GSM+40) 3.912 – 4.248 -0.336 -2.672 0.8978 
(Plaque area)1/3 4.309 – 3.4200 0.889 0.629 0.5592 
DWA 1 – 0 1 0.429 0.4290 
History of contrala-
teral TIAs and/or 
stroke 
0 – 0 0 0.973 0 
 
4. Sum of βx = βx = 0.2600 + 0.8978 + 0.5592 + 0.4290 + 0 = 2.1460 
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5. exp(2.146) = 8.551 
 
6. Predicted 5-year stroke free survival 100 x 0.972exp(2.146) = 78.4% 
 
CAPTIONS FOR FIGURES 
 
Figure 1 
Kaplan-Meier plots showing ipsilateral CORI event free survival stratified by: 
(a)ECST stenosis: Log rank test: P for trend = 0.002 
(b) GSM: Log rank test: P for trend < 0.0001 
(c) Plaque area (mm2): Log rank test: P for trend < 0.0001  
(d) DWA: Log rank test: P < 0.0001  
(e) History of contralateral TIAs or stroke: Log rank test: P < 0.0001  
 
Figure 2 
(A) ROC curves for CORI events using (a) stenosis as continuous variable, (b) the lin-
ear predictor score from the proportional hazards model (model i) that included steno-
sis and significant clinical features only (recruitment, pack-years, history of contrala-
teral TIAs or stroke) and (c) the proportional hazards model (model ii) that included 
stenosis, significant clinical and plaque characteristics (GSM, plaque area, DWA and 
history of contralateral TIAs or stroke) for predicting ipsilateral CORI events. Corre-
sponding areas under curve are (a) 0.59 (95% CI 0.54 to 0.64), (b) 0.66 (95% CI 0.62 
to 0.72) and (c) 0.82 (95% CI 0.78 to 0.86). P < 0.003 for all pairwise comparisons. 
(B) ROC curve for stroke using the linear predictor score of the proportional hazards 
model (model iii). Area under curve is 0.80 (95% CI 0.74 to 0.86). 
 
Figure 3 
Calibration plot for model (iii), based on all 1121 patients. 
– – –  shows the line of perfect agreement between predicted and observed 5-year 
stroke risk. 
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